Advertisement
BRKR vs DHR
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- BRKR and DHR operate in overlapping life sciences and analytical instruments sectors, with BRKR focused on specialized scientific tools and DHR maintaining a broader diversified portfolio across diagnostics and bioprocessing.
- Recent market activity shows BRKR exhibiting higher volatility with notable year-to-date gains amid partnerships in fusion technology and semiconductor metrology, while DHR demonstrates steadier performance supported by core revenue growth and a leadership transition.
- Both companies reported Q2 2026 results reflecting modest organic growth, with BRKR highlighting efficiency gains and DHR raising full-year guidance following acquisitions and improved non-respiratory volumes.
- Sector exposure positions BRKR with greater sensitivity to academic and industrial research spending, whereas DHR benefits from diversified end markets including biopharma and diagnostics.
- Market sentiment reflects BRKR's momentum in niche high-tech applications contrasted with DHR's emphasis on operational discipline and shareholder returns through dividends.
- Relative performance underscores trade-offs between BRKR's growth potential in emerging areas like spatial biology and DHR's scale advantages in stability and cash flow generation.
Introduction
BRKR and DHR represent two prominent players in the life sciences tools and diagnostics space, making their comparison relevant for investors seeking exposure to scientific instrumentation and healthcare technology. Traders monitoring relative performance in the healthcare equipment sector may find this analysis useful when evaluating positioning amid evolving research funding, biopharma demand, and technological advancements. The comparison highlights contrasts in business scale, recent momentum, and market positioning without favoring either security.
BRKR Overview and Recent Performance
Bruker Corporation develops and manufactures scientific instruments and analytical solutions for life sciences, materials research, and industrial applications. In recent weeks, the stock has shown notable volatility alongside positive developments including collaborations on superconductors for fusion power projects and presentations at major healthcare investor conferences. Q2 2026 results indicated reported revenue growth of approximately 5%, supported by operational efficiencies, though tempered by a noncash impairment charge. Sentiment has been influenced by strength in semiconductor metrology and preclinical imaging segments, with management reaffirming fiscal 2026 guidance amid broader market activity in research tools.
DHR Overview and Recent Performance
Danaher Corporation operates as a diversified science and technology company with key segments in life sciences, diagnostics, and environmental solutions. Recent market activity reflects steady performance following Q2 2026 results that showed core revenue growth and an upward revision to full-year adjusted earnings per share guidance. The company announced a new president and chief executive officer in August 2026 and declared its regular quarterly dividend. Broader sentiment has been supported by improved execution in bioprocessing and life sciences end markets, alongside disciplined capital allocation including share repurchases, contributing to relative stability in the large-cap healthcare space.
Trending AI Robots
Tickeron maintains a curated selection of AI-powered trading robots designed to identify opportunities across thousands of tickers using adaptive models on various timeframes. Hundreds of such bots are available on the platform, each employing distinct trading styles, strategies, and performance statistics, but only the highest-ranked and most suitable for prevailing conditions appear in the Trending AI Robots section—currently featuring 30 selections out of 298 total robots. Performance metrics for featured agents often highlight strong historical annualized returns alongside indicators such as win rates and risk-adjusted measures. All bots differ in their approaches to momentum, trend following, or hedging. For more details on these tools, visit the Trending AI Robots page.
Head-to-Head Comparison
BRKR and DHR differ markedly in scale and focus: BRKR concentrates on specialized analytical and diagnostic instrumentation with exposure to academic and industrial research cycles, while DHR's diversified model spans multiple healthcare verticals and benefits from greater revenue stability. Recent momentum favors BRKR in niche areas such as metrology and fusion-related technologies, contrasted with DHR's emphasis on core growth acceleration and acquisition integration. Risk factors include BRKR's higher beta and sensitivity to research spending fluctuations versus DHR's lower volatility but exposure to biopharma capital expenditure cycles. Sector positioning places both in life sciences tools, yet BRKR's smaller market capitalization offers potentially higher upside in targeted innovations, while DHR provides broader diversification and consistent dividend payouts. Market sentiment reflects these trade-offs, with BRKR showing stronger recent percentage gains in certain periods amid innovation catalysts and DHR demonstrating resilience through operational metrics.
Tickeron AI Verdict
Based on observable factors including trend consistency in recent market activity, stability metrics, and relative positioning within the life sciences sector, Tickeron’s AI would currently assign a probabilistic edge to DHR for its demonstrated core revenue resilience and guidance updates, though BRKR's momentum in specialized segments warrants monitoring for potential outperformance in targeted scenarios. This assessment relies on verifiable performance patterns rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a StrongBuy and DHR is a Buy.
BRKR | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 77 | |
PRICE GROWTH RATING 1..100 | 36 | 53 | |
P/E GROWTH RATING 1..100 | 5 | 42 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is somewhat better than the same rating for BRKR (59). This means that DHR’s stock grew somewhat faster than BRKR’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BRKR (100). This means that DHR’s stock grew similarly to BRKR’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as BRKR (92). This means that DHR’s stock grew similarly to BRKR’s over the last 12 months.
BRKR's Price Growth Rating (36) in the Medical Specialties industry is in the same range as DHR (53). This means that BRKR’s stock grew similarly to DHR’s over the last 12 months.
BRKR's P/E Growth Rating (5) in the Medical Specialties industry is somewhat better than the same rating for DHR (42). This means that BRKR’s stock grew somewhat faster than DHR’s over the last 12 months.
| BRKR | DHR | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 55% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 72% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 65% |
| Advances ODDS (%) | 3 days ago 69% | 5 days ago 54% |
| Declines ODDS (%) | 10 days ago 74% | 2 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 57% |
| Aroon ODDS (%) | N/A | 2 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while DHR’s FA Score has 1 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 4 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- BRKR’s TA Score: 4 bullish, 4 bearish.
- DHR’s TA Score: 4 bullish, 6 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -3.22% price change this week, while DHR (@Medical Specialties) price change was -5.20% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.19%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -2.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.42%. For the same industry, the average monthly price growth was +3.09%, and the average quarterly price growth was +45.49%.
Reported Earning Dates
BRKR is expected to report earnings on Oct 29, 2026.
DHR is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.42% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| TLM.X | 0.001619 | 0.000087 | +5.66% |
| Alien Worlds cryptocurrency | |||
| SAND.X | 0.044939 | 0.001113 | +2.54% |
| The Sandbox cryptocurrency | |||
| STEEM.X | 0.063852 | -0.001204 | -1.85% |
| Steem cryptocurrency | |||
| ALPHA.X | 0.000420 | -0.000009 | -2.13% |
| Stella cryptocurrency | |||
| NEAR.X | 4.806079 | -0.530614 | -9.94% |
| NEAR Protocol cryptocurrency | |||
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -4.42% | ||
| TMO - DHR | 73% Closely correlated | -3.34% | ||
| RGEN - DHR | 68% Closely correlated | -7.80% | ||
| BIO - DHR | 64% Loosely correlated | -5.86% | ||
| A - DHR | 60% Loosely correlated | -3.27% | ||
| BRKR - DHR | 58% Loosely correlated | -4.34% | ||
More | ||||